AR056245A1 - FUNCTIONAL RECONSTITUTED VIRAL MEMBRANES CONTAINING A COADYUVANT - Google Patents
FUNCTIONAL RECONSTITUTED VIRAL MEMBRANES CONTAINING A COADYUVANTInfo
- Publication number
- AR056245A1 AR056245A1 ARP040102097A ARP040102097A AR056245A1 AR 056245 A1 AR056245 A1 AR 056245A1 AR P040102097 A ARP040102097 A AR P040102097A AR P040102097 A ARP040102097 A AR P040102097A AR 056245 A1 AR056245 A1 AR 056245A1
- Authority
- AR
- Argentina
- Prior art keywords
- coadyuvant
- membranes
- viral membranes
- membranes containing
- reconstituted viral
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title abstract 4
- 230000003612 virological effect Effects 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 229930186217 Glycolipid Natural products 0.000 abstract 1
- 108010028921 Lipopeptides Proteins 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000034217 membrane fusion Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Vacunas dirigidas contra antígenos, tales como las proteínas de membrana de patogenos o células tumorales. Método para formar membranas virales reconstruidos, con actividad de fusion de membranas, que son membranas con dos capas de lípidos que contienen preferiblemente lípidos naturales de un virus, una proteína de fusion viral, uno o más antígenos adicionales opcionales, así como coadyuvantes anfifílicos, como por ejemplo lipopéptidos, glicolípidos o péptidos, entre otros. Las composiciones farmacéuticas que comprenden dichas membranas virales reconstruidas.Vaccines directed against antigens, such as pathogen membrane proteins or tumor cells. Method for forming reconstructed viral membranes, with membrane fusion activity, which are membranes with two layers of lipids that preferably contain natural lipids of a virus, a viral fusion protein, one or more optional additional antigens, as well as amphiphilic adjuvants, such as for example lipopeptides, glycolipids or peptides, among others. The pharmaceutical compositions comprising said reconstructed viral membranes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL0300450 | 2003-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056245A1 true AR056245A1 (en) | 2007-10-03 |
Family
ID=33550371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102097A AR056245A1 (en) | 2003-06-19 | 2004-06-16 | FUNCTIONAL RECONSTITUTED VIRAL MEMBRANES CONTAINING A COADYUVANT |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7618641B2 (en) |
| EP (2) | EP1633395B1 (en) |
| JP (1) | JP4685005B2 (en) |
| KR (1) | KR101225199B1 (en) |
| CN (1) | CN100556454C (en) |
| AR (1) | AR056245A1 (en) |
| AU (1) | AU2004246974B2 (en) |
| BR (1) | BRPI0411519A (en) |
| CA (1) | CA2527735C (en) |
| DK (2) | DK1633395T3 (en) |
| ES (2) | ES2390454T3 (en) |
| IL (1) | IL172584A (en) |
| MX (1) | MXPA05013929A (en) |
| NO (1) | NO20055934L (en) |
| PL (2) | PL1633395T3 (en) |
| RU (1) | RU2348428C2 (en) |
| TW (1) | TWI329130B (en) |
| UA (1) | UA87269C2 (en) |
| WO (1) | WO2004110486A1 (en) |
| ZA (1) | ZA200509907B (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006078164A2 (en) | 2005-01-18 | 2006-07-27 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Mycobacteria with mannose cap-deficient lipoarabinomannan |
| AR059972A1 (en) * | 2006-03-22 | 2008-05-14 | Solvay Pharm Bv | VIROSOMAS INTRANASAL OR INHALATIONAL ADMINISTRATION |
| TWI397419B (en) * | 2006-03-22 | 2013-06-01 | Abbott Biologicals Bv | Intranasal or inhalational administration of virosomes |
| US8535683B2 (en) | 2006-03-22 | 2013-09-17 | Abbott Biologicals B.V. | Intranasal or inhalational administration of virosomes |
| US8916164B2 (en) * | 2007-08-29 | 2014-12-23 | Abivax | Methods of enhancing adjuvaticity of vaccine compositions |
| EP2058002A1 (en) | 2007-10-31 | 2009-05-13 | Bestewil Holding B.V. | Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine |
| CA2750058C (en) | 2009-02-06 | 2017-11-28 | Mymetics Corporation | Novel gp41 antigens |
| KR20110126636A (en) | 2009-02-06 | 2011-11-23 | 마이메틱스 코포레이션 | Splitting gp41 |
| CA2792938C (en) | 2010-03-23 | 2018-07-31 | Irm Llc | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| WO2011128720A1 (en) | 2010-04-14 | 2011-10-20 | Mymetics Corporation | Trans-activator of transcription protein |
| EP2608802B1 (en) | 2010-08-27 | 2017-02-22 | Pantarhei Bioscience B.V. | Immunotherapeutic method for treating prostate cancer |
| US20130259928A1 (en) * | 2010-09-30 | 2013-10-03 | Franvax S.R.L. | Generation of virosome particles |
| US10806779B2 (en) | 2013-07-02 | 2020-10-20 | Janssen Vaccines & Prevention B.V. | Method for preparing virosomes |
| NZ730357A (en) | 2014-09-12 | 2021-12-24 | Bestewil Holding Bv | Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby |
| WO2016039620A2 (en) | 2014-09-12 | 2016-03-17 | Bestewil Holding B.V. | Respiratory syncytial virus virosomes |
| WO2016080830A2 (en) | 2014-11-18 | 2016-05-26 | Pantarhei Bioscience B.V. | Immunotherapeutic method for treating pancreatic cancer |
| CN111511392A (en) | 2017-10-31 | 2020-08-07 | 潘塔希生物科学股份有限公司 | Immunotherapeutic method for the treatment and/or prevention of lung cancer |
| US20210317165A1 (en) | 2018-09-03 | 2021-10-14 | Laboratoire Hra-Pharma | Zp3 fragments in immunotherapy of ovarian cancer |
| US11523988B2 (en) | 2018-11-29 | 2022-12-13 | Catalent U.K. Swindon Zydis Limited | Oral dispersible vaccine comprising virosomes |
| US20200188511A1 (en) | 2018-12-12 | 2020-06-18 | Anergis S.A. | Methods of improving efficacy of allergy vaccines |
| WO2021207303A1 (en) * | 2020-04-07 | 2021-10-14 | Alsatech, Inc. | Immune stimulation against coronavirus infections |
| WO2023066923A1 (en) | 2021-10-19 | 2023-04-27 | Rahman Nafis | Male contraception |
| WO2023237726A1 (en) | 2022-06-10 | 2023-12-14 | Pantarhei Oncology B.V. | An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer |
| WO2024088138A1 (en) * | 2022-10-25 | 2024-05-02 | 宁波明亦生物科技有限公司 | Plasma membrane-permeabilized inactivated oral vaccine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4542212A (en) | 1975-10-14 | 1985-09-17 | Institut Pasteur | Phosphorylated 3-glyceryl-esters of glucose |
| JPS5929931B2 (en) * | 1980-12-09 | 1984-07-24 | オムロン株式会社 | safety switch |
| SE8205892D0 (en) | 1982-10-18 | 1982-10-18 | Bror Morein | IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF |
| SE8405493D0 (en) | 1984-11-01 | 1984-11-01 | Bror Morein | IMMUNOGENT COMPLEX AND KITCHEN FOR PREPARING IT AND USING IT AS IMMUNOSTIMENTING AGENTS |
| JPH0688911B2 (en) | 1985-06-06 | 1994-11-09 | 国立予防衛生研究所長 | Influenza vaccine and method for producing the same |
| DE3775783D1 (en) | 1986-01-14 | 1992-02-20 | Nederlanden Staat | METHOD FOR PRODUCING IMMUNOLOGICAL COMPLEXES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM. |
| NZ224422A (en) | 1987-05-05 | 1990-11-27 | Molecular Eng Ass | Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid |
| CA2054228A1 (en) | 1990-10-30 | 1992-05-01 | Masaharu Oki | Muramyldipeptide derivatives and influenza vaccine comprising the derivatives |
| US5879685A (en) | 1991-05-08 | 1999-03-09 | Schweiz, Serum- & Impfinstitut Bern | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
| ES2135406T3 (en) | 1991-05-08 | 1999-11-01 | Schweiz Serum & Impfinst | INFLUENZA VIROSOMES RECONSTITUTED IMMUNO-STIMULANTS AND IMMUNOPOTENTIALIZERS AND VACCINES THAT CONTAIN THEM. |
| US20030113347A1 (en) | 1991-05-08 | 2003-06-19 | Schweiz. Serum- & Impfinstitut Bern | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| AU2284697A (en) * | 1996-04-11 | 1997-10-29 | University Of British Columbia, The | Fusogenic liposomes |
| AU2001238478C1 (en) | 2000-02-15 | 2006-11-09 | Id Biomedical Corporation Of Quebec | Proteosome influenza vaccine |
| GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
| WO2004045641A2 (en) * | 2002-11-20 | 2004-06-03 | Crucell Holland B.V. | Antigen-complexes |
| US7491395B2 (en) * | 2002-11-20 | 2009-02-17 | Bestewil Holding B.V. | Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination |
-
2004
- 2004-06-16 TW TW093117276A patent/TWI329130B/en not_active IP Right Cessation
- 2004-06-16 AR ARP040102097A patent/AR056245A1/en unknown
- 2004-06-18 UA UAA200512191A patent/UA87269C2/en unknown
- 2004-06-18 BR BRPI0411519-8A patent/BRPI0411519A/en not_active Application Discontinuation
- 2004-06-18 DK DK04748669.1T patent/DK1633395T3/en active
- 2004-06-18 PL PL04748669T patent/PL1633395T3/en unknown
- 2004-06-18 KR KR1020057024393A patent/KR101225199B1/en active IP Right Grant
- 2004-06-18 EP EP04748669A patent/EP1633395B1/en not_active Expired - Lifetime
- 2004-06-18 ES ES04748669T patent/ES2390454T3/en not_active Expired - Lifetime
- 2004-06-18 CN CNB2004800167589A patent/CN100556454C/en not_active Expired - Fee Related
- 2004-06-18 WO PCT/NL2004/000437 patent/WO2004110486A1/en active Application Filing
- 2004-06-18 DK DK10180937.4T patent/DK2368576T3/en active
- 2004-06-18 RU RU2006101394/15A patent/RU2348428C2/en active
- 2004-06-18 MX MXPA05013929A patent/MXPA05013929A/en active IP Right Grant
- 2004-06-18 AU AU2004246974A patent/AU2004246974B2/en not_active Ceased
- 2004-06-18 EP EP10180937.4A patent/EP2368576B1/en not_active Expired - Lifetime
- 2004-06-18 US US10/560,594 patent/US7618641B2/en active Active
- 2004-06-18 JP JP2006516989A patent/JP4685005B2/en not_active Expired - Fee Related
- 2004-06-18 CA CA2527735A patent/CA2527735C/en not_active Expired - Lifetime
- 2004-06-18 ES ES10180937.4T patent/ES2536689T3/en not_active Expired - Lifetime
- 2004-06-18 PL PL10180937T patent/PL2368576T3/en unknown
-
2005
- 2005-12-06 ZA ZA200509907A patent/ZA200509907B/en unknown
- 2005-12-14 IL IL172584A patent/IL172584A/en unknown
- 2005-12-14 NO NO20055934A patent/NO20055934L/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056245A1 (en) | FUNCTIONAL RECONSTITUTED VIRAL MEMBRANES CONTAINING A COADYUVANT | |
| Kuate et al. | Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies | |
| CO2020001872A2 (en) | Preparation of therapeutic exosomes by using membrane proteins | |
| CN113521268A (en) | Coronavirus vaccine | |
| EA201391467A1 (en) | LIPOSOMIC COMPOSITIONS | |
| JP2016519933A5 (en) | ||
| WO2007044731A3 (en) | Recombinant proteins from filoviruses and their use | |
| CO6491045A2 (en) | PROTEIN F COMPOSITIONS OF RESPIRATORY SYNCTIAL VIRUS (RSV) AND METHODS TO PRODUCE THE SAME | |
| JP2023526178A (en) | coronavirus vaccine | |
| EA200900784A1 (en) | VACCINES INCLUDING ANTIGENS FROM FOUR STRAINS OF THE INFLUENZA VIRUS | |
| CL2013003634A1 (en) | Complex comprising a fusion protein comprising, a viral peptide, linker peptide, beta 2 microglobulin, linker peptide, extracellular domains alpha 1, 2 and 3 of mhc class i and a third linker peptide; Method of production; pharmaceutical formulation that includes it; and its use | |
| CY1113934T1 (en) | DRIED REFRIGERATED CYLINDER FORMATION FOR PHARMACEUTICAL APPLICATION | |
| AR061894A1 (en) | VACCINES FOR MALARIA | |
| BR112013012555B8 (en) | ISOLATED IMMUNOGENIC PEPTIDE DERIVED FROM AN ANTIGEN PROTEIN, ITS USES, METHOD FOR THE PREPARATION OF A PEPTIDE WITH THE CAPACITY OF PROVOKING THE ACTIVATION OF NKT CELLS AND IN VITRO METHOD FOR OBTAINING A SPECIFIC ANTIGEN CD4+ NKT CELL POPULATION | |
| ES2190799T3 (en) | PEPTIDIC IMMUNOGENS FOR VACCINATION AND TREATMENT OF ALLERGY. | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| UY33297A (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A POLYPEPTIDE THAT UNDERSTANDS AT LEAST A CXXC REASON AND HETEROLOGICAL ANTIGENS AND USES OF THE SAME | |
| WO2007008070A3 (en) | ADJUVATION THROUGH CROSS-β STRUCTURE | |
| WO2013076580A3 (en) | Recombinant proteins and their therapeutic uses | |
| EA201391200A1 (en) | METHODS AND COMPOSITIONS FOR VACCINATION FROM STAPHYLOCOCCUS AUREUS | |
| EA202090700A1 (en) | REPLICATION-COMPETENT ADENOVIRAL VECTORS | |
| EA201790680A1 (en) | VACCINES AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) CONTAINING ONE OR MORE EPISENSUS (EPISENSUS) FOR POPULATION OF ANTIGENES | |
| TW202333780A (en) | Coronavirus vaccine | |
| ATE544470T1 (en) | IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS | |
| WO2006071896A3 (en) | Epitope-based sars vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |